Optimal subsite occupancy and design of a selective inhibitor of urokinase

被引:93
作者
Ke, SH
Coombs, GS
Tachias, K
Corey, DR
Madison, EL
机构
[1] Scripps Res Inst, DEPT VASC BIOL VB1, LA JOLLA, CA 92037 USA
[2] UNIV TEXAS, SW MED CTR, DEPT PHARMACOL, DALLAS, TX 75235 USA
[3] UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA
关键词
D O I
10.1074/jbc.272.33.20456
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human urokinase type plasminogen activator (u-PA) is a member of the chymotrypsin family of serine proteases that can play important roles in both health and disease, We have used substrate phage display techniques to characterize the specificity of this enzyme in detail and to identify peptides that are cleaved 840-5300 times more efficiently by u-PA than peptides containing the physiological target sequence of the enzyme, In addition, unlike peptides containing the physiological target sequence, the peptide substrates selected in this study were cleaved as much as 120 times more efficiently by u-PA than by tissue type plasminogen activator (t-PA), an intimately related enzyme. Analysis of the selected peptide substrates strongly suggested that the primary sequence SGRSA, from position P3 to P2', represents optimal subsite occupancy for substrates of u-PA. Insights gained in these investigations were used to design a variant of plasminogen activator inhibitor type 1, the primary physiological inhibitor of both u-PA and t-PA, that inhibited u-PA approximately 70 times more rapidly than it inhibited t-PA. These observations provide a solid foundation for the design of highly selective, high affinity inhibitors of u-PA and, consequently, may facilitate the development of novel therapeutic agents to inhibit the initiation and/or progression of selected human tumors.
引用
收藏
页码:20456 / 20462
页数:7
相关论文
共 52 条
[1]  
ADAMS DS, 1991, J BIOL CHEM, V266, P8476
[2]   HYDROPHILIC-INTERACTION CHROMATOGRAPHY FOR THE SEPARATION OF PEPTIDES, NUCLEIC-ACIDS AND OTHER POLAR COMPOUNDS [J].
ALPERT, AJ .
JOURNAL OF CHROMATOGRAPHY, 1990, 499 :177-196
[3]  
BAGGIO R, 1996, BIOCHEMISTRY-US, V35, P3551
[4]  
BEATTY K, 1980, J BIOL CHEM, V255, P3931
[5]  
BODE W, 1992, PROTEIN SCI, V1, P426
[6]  
BRUNNER N, 1992, Proceedings of the American Association for Cancer Research Annual Meeting, V33, P61
[7]   Targeted gene manipulation and transfer of the plasminogen and coagulation systems in mice [J].
Carmeliet, P ;
Collen, D .
FIBRINOLYSIS, 1996, 10 (04) :195-213
[8]   PHYSIOLOGICAL CONSEQUENCES OF LOSS OF PLASMINOGEN-ACTIVATOR GENE-FUNCTION IN MICE [J].
CARMELIET, P ;
SCHOONJANS, L ;
KIECKENS, L ;
REAM, B ;
DEGEN, J ;
BRONSON, R ;
DEVOS, R ;
VANDENOORD, JJ ;
COLLEN, D ;
MULLIGAN, RC .
NATURE, 1994, 368 (6470) :419-424
[9]  
Castellino F. J., 1995, MOL BASIS THROMBOSIS, P495
[10]   P-NITROPHENYL-P'-GUANIDINOBENZOATE HCL - A NEW ACTIVE SITE TITRANT FOR TRYPSIN [J].
CHASE, T ;
SHAW, E .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1967, 29 (04) :508-&